WSI "EasyMediBot Obtains Domestic Patent for Surgical Robot"

WSI, a specialized company in pharmaceutical and medical device distribution, has been recognized for its differentiated technology with the acquisition of a patent for a laparoscopic surgery support robot for gynecologic cancer and related disease treatment developed by its subsidiary EasyMedibot.

On the 27th, WSI announced that EasyMedibot obtained a domestic patent for a 'Primary·Secondary type uterine retractor that can operate automatically according to user input.'

The uterine retractor developed by EasyMedibot is a surgical assist robot used in gynecologic laparoscopic surgery. It allows precise control of the retractor’s posture and direction based on user input, enabling more accurate and faster surgeries. Additionally, it helps prevent damage to the patient’s uterus and surrounding tissues.

For successful laparoscopic surgery, securing the field of view of the endoscopic camera inserted into the abdominal cavity and ensuring space for manipulating surgical instruments are essential. In particular, during gynecologic laparoscopic surgery, the uterus can obstruct the view or interfere with surgical tools, requiring frequent adjustment of the uterus’s posture and position during surgery. However, manual retractors operated by medical staff during conventional gynecologic laparoscopic surgeries have limitations in fine adjustments and control. Moreover, the movements of existing gynecologic laparoscopic surgical robots are not ergonomic, causing damage to patient tissues or lymph nodes.

The uterine retractor patented by EasyMedibot this time is designed to overcome the limitations of existing gynecologic laparoscopic surgical robots, such as delayed surgery time and uterine damage. Even medical staff unfamiliar with the use of existing gynecologic surgical robots can easily utilize this surgical robot.

A WSI official stated, "The robot-assisted uterine retractor developed by EasyMedibot applies intuitive operation methods and ergonomic movements, enabling safe and efficient surgery even in narrow spaces. Starting with this patent acquisition, we will accelerate global patent acquisitions, approval from the Ministry of Food and Drug Safety, and product launches to expand our surgical robot business."

Meanwhile, WSI is actively targeting the global surgical robot market. To this end, it is currently filing patents for the uterine retractor in the United States and Europe. In October, the company also established a partnership with EasyMedibot and China’s LifeTech Scientific Corp group to develop and commercialize surgical robots. The three companies plan to leverage their respective R&D capabilities and networks to commercialize surgical robots as soon as possible.

This content was produced with the assistance of AI translation services.